Syndax Pharmaceuticals, Inc.
SNDX
$18.79
-$0.33-1.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 538.71% | 1,866.34% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 597.19% | 2,133.71% | -- | -- | -- |
| Cost of Revenue | 25.04% | -4.36% | -5.58% | -6.27% | 48.50% |
| Gross Profit | 72.70% | 58.06% | 39.48% | 24.63% | -26.83% |
| SG&A Expenses | 58.01% | 66.76% | 78.10% | 80.63% | 95.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.02% | 43.05% | 47.04% | 58.01% | 73.75% |
| Operating Income | 4.53% | -17.64% | -30.45% | -47.71% | -65.50% |
| Income Before Tax | -4.89% | -26.85% | -37.64% | -52.25% | -68.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.89% | -26.85% | -37.64% | -52.25% | -68.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.89% | -26.85% | -37.64% | -52.25% | -68.71% |
| EBIT | 4.53% | -17.64% | -30.45% | -47.71% | -65.50% |
| EBITDA | 4.53% | -17.65% | -30.45% | -47.72% | -65.51% |
| EPS Basic | 0.45% | -15.38% | -19.97% | -25.83% | -40.47% |
| Normalized Basic EPS | 0.45% | -15.38% | -19.97% | -25.83% | -40.48% |
| EPS Diluted | 0.64% | -15.15% | -19.83% | -25.70% | -40.63% |
| Normalized Diluted EPS | 0.45% | -15.38% | -19.97% | -25.83% | -40.48% |
| Average Basic Shares Outstanding | 5.02% | 9.87% | 15.29% | 21.41% | 20.70% |
| Average Diluted Shares Outstanding | 5.02% | 9.87% | 15.29% | 21.41% | 20.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |